{
    "root": "8036f480-a038-4797-afdb-4b1e631eacd8",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Fluticasone Propionate and Salmeterol HFA",
    "value": "20240529",
    "ingredients": [
        {
            "name": "FLUTICASONE PROPIONATE",
            "code": "O2GMZ0LF5W",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31441"
        },
        {
            "name": "SALMETEROL XINAFOATE",
            "code": "6EW8Q962A5",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9012"
        },
        {
            "name": "NORFLURANE",
            "code": "DH9E53K1Y8",
            "drugbank_id": "https://go.drugbank.com/drugs/DB13116"
        }
    ],
    "indications": {
        "text": "fluticasone propionate salmeterol hfa indicated treatment asthma adult adolescent patients aged 12 years older . fluticasone propionate salmeterol hfa used patients adequately controlled long-term asthma control medication inhaled corticosteroid ( ics ) whose disease warrants initiation treatment ics long-acting beta2-adrenergic agonist ( laba ) . limitations fluticasone propionate salmeterol hfa indicated relief acute bronchospasm .",
        "doid_entities": [
            {
                "text": "asthma (DOID:2841)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2841"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 oral inhalation . ( 2.1 ) \u2022 adult adolescent patients aged 12 years older : 2 inhalations fluticasone propionate salmeterol hfa 45 mcg/21 mcg , fluticasone propionate salmeterol hfa 115 mcg/21 mcg , fluticasone propionate salmeterol hfa 230 mcg/21 mcg twice daily . ( 2.2 ) \u2022 starting based asthma severity . ( 2.2 )",
        "doid_entities": [
            {
                "text": "asthma (DOID:2841)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2841"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "fluticasone propionate salmeterol hfa supplied following boxes 1 pressurized aluminum canister fitted counter supplied purple plastic actuator light purple cap : \u2022fluticasone propionate salmeterol hfa 45 mcg/21 mcg : 12-g canister containing 120 actuations ( ndc 66993-086-96 ) \u2022fluticasone propionate salmeterol hfa 115 mcg/21 mcg : 12-g canister containing 120 actuations ( ndc 66993-087-96 ) \u2022fluticasone propionate salmeterol hfa 230 mcg/21 mcg : 12-g canister containing 120 actuations ( ndc 66993-088-96 ) inhaler packaged patient information leaflet . purple actuator supplied fluticasone propionate salmeterol hfa used product canisters , actuators products used fluticasone propionate salmeterol hfa canister . counter fluticasone propionate salmeterol hfa counter attached canister . counter starts 124 counts time spray released . correct amount medication actuation assured counter reads 000 , even though canister completely empty continue operate . inhaler discarded counter reads 000. contents pressure puncture . store near heat open flame . exposure temperatures 120\u00b0f may cause bursting . never throw canister fire incinerator . storage store room temperature 68\u00b0f 77\u00b0f ( 20\u00b0c 25\u00b0c ) ; excursions permitted 59\u00b0f 86\u00b0f ( 15\u00b0c 30\u00b0c ) [ usp controlled room temperature ] . store inhaler mouthpiece . best results , inhaler room temperature .",
    "adverseReactions": "fluticasone propionate salmeterol hfa contraindicated following conditions : \u2022primary treatment status asthmaticus acute episodes asthma intensive measures required [ ( 5.2 ) ] . \u2022hypersensitivity ingredients [ ( 5.11 ) , ( 6.2 ) , description ( 11 ) ] .",
    "indications_original": "Fluticasone Propionate and Salmeterol HFA is indicated for treatment of asthma in adult and adolescent patients aged 12\u00a0years and older. Fluticasone Propionate and Salmeterol HFA should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an ICS and long-acting beta2-adrenergic agonist (LABA).\n                  \n                     Limitations of Use\n                  \n                  Fluticasone Propionate and Salmeterol HFA is not indicated for the relief of acute bronchospasm.",
    "contraindications_original": "\u2022 For oral inhalation only. ( 2.1 ) \u2022 Adult and adolescent patients aged 12 years and older: 2 inhalations of Fluticasone Propionate and Salmeterol HFA 45 mcg/21 mcg, Fluticasone Propionate and Salmeterol HFA 115\u00a0mcg/21\u00a0mcg, or Fluticasone Propionate and Salmeterol HFA 230 mcg/21 mcg twice daily. ( 2.2 ) \u2022 Starting dosage is based on asthma severity. ( 2.2 )",
    "warningsAndPrecautions_original": "Fluticasone Propionate and Salmeterol HFA is supplied in the following boxes of 1 as a pressurized aluminum canister fitted with a counter and supplied with a purple plastic actuator with a light purple cap:\n                  \n                     \n                        \u2022Fluticasone Propionate and Salmeterol HFA 45 mcg/21 mcg: 12-g canister containing 120 actuations (NDC 66993-086-96)\n                     \n                        \u2022Fluticasone Propionate and Salmeterol HFA 115 mcg/21 mcg: 12-g canister containing 120 actuations (NDC 66993-087-96)\n                     \n                        \u2022Fluticasone Propionate and Salmeterol HFA 230 mcg/21 mcg: 12-g canister containing 120 actuations (NDC 66993-088-96)\n                  \n                  Each inhaler is packaged with a Patient Information leaflet.\n                  The purple actuator supplied with Fluticasone Propionate and Salmeterol HFA should not be used with any other product canisters, and actuators from other products should not be used with a Fluticasone Propionate and Salmeterol HFA canister.\n                  \n                     Counter\n                  \n                  Fluticasone Propionate and Salmeterol HFA has a counter attached to the canister. The counter starts at 124 and counts down each time a spray is released. The correct amount of medication in each actuation cannot be assured after the counter reads 000, even though the canister is not completely empty and will continue to operate. The inhaler should be discarded when the counter reads 000.\n                  \n                     Contents under Pressure\n                  \n                  Do not puncture. Do not use or store near heat or open flame. Exposure to temperatures above 120\u00b0F may cause bursting. Never throw canister into fire or incinerator.\n                  \n                     Storage\n                  \n                  Store at room temperature between 68\u00b0F and 77\u00b0F (20\u00b0C and 25\u00b0C); excursions permitted from 59\u00b0F to 86\u00b0F (15\u00b0C to 30\u00b0C) [See USP Controlled Room Temperature]. Store the inhaler with the mouthpiece down. For best results, the inhaler should be at room temperature before use.",
    "adverseReactions_original": "Fluticasone Propionate and Salmeterol HFA is contraindicated in the following conditions:\n                  \n                     \n                        \u2022Primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required [see Warnings and Precautions (5.2)].\n                     \n                        \u2022Hypersensitivity to any of the ingredients [see Warnings and Precautions (5.11), Adverse Reactions (6.2), Description (11)].",
    "drug": [
        {
            "name": "Fluticasone Propionate and Salmeterol HFA",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5134"
        }
    ]
}